The FDA approved Milestone Pharmaceuticals’ nasally administered emergency treatment Cardamyst (etripamil) for acute supraventricular arrhythmias after two prior rejections. The approval provides a non‑injectable, rapid‑acting option for ambulatory management of select arrhythmias that historically required clinic or emergency care. Milestone’s clearance changes outpatient acute-care pathways by enabling at‑home or first‑responder administration, which may reduce ED visits and shift emergency treatment standards. The decision follows additional data submissions that addressed regulators’ prior safety and efficacy concerns; cardiology practices and device/pharma competitors will assess how the new route affects market adoption and reimbursement.